Posted by Michael Wonder on 02 Oct 2020
Proposal to widen access to sirolimus for lymphovascular malformations and tuberous sclerosis complex complications
2 October 2020 - PHARMAC is seeking feedback on a proposal to widen funded access to sirolimus from 1 February 2021 for patients with indications as below:
- Lymphovascular malformations
- Renal angiomyolipoma associated with tuberous sclerosis complex
- Refractory epilepsy associated with tuberous sclerosis complex
